https://orcid.org/0000-0003-0323-7030
-
Views
-
Cite
Cite
Mohamed Attauabi, Johan Burisch, Ole Haagen Nielsen, Jakob Benedict Seidelin, In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis, Inflammatory Bowel Diseases, Volume 30, Issue 10, October 2024, Pages 1931–1932, https://doi.org/10.1093/ibd/izae183
Close - Share Icon Share
Extract
To the Editors
We read with interest the article by Dalal et al.,1 which reports favorable short-term clinical outcomes of upadacitinib 45 mg daily in patients with acute severe ulcerative colitis (UC). The study demonstrates high rates (86%) of steroid-free clinical remission 8-16 weeks after treatment initiation in a real-world setting with 7 of the 9 patients being steroid-refractory and having prior exposure to tumor necrosis factor inhibitor therapy.
Given the urgency in managing acute severe UC, where rapid deterioration can lead to severe complications and consequently the need for colectomy, the speed of onset of therapeutic effects is not merely beneficial but crucial to improve patient outcomes. In addition, there exists a prevailing conception that therapeutic effects manifest more rapidly in UC than in Crohn’s disease (CD).2 Therefore, we seek additional details on the induction of clinical remission during the hospital stay beyond the presented C-reactive protein reductions on day 2, provided such data are available.
